Paulo Jorge Barradas de Oliveira Rebelo
Directeur Général chez Bluepharma Indústria Farmacêutica SA
Profil
Paulo Jorge Barradas de Oliveira Rebelo is currently the President & Chief Executive Officer at Bluepharma Indústria Farmacêutica SA. He is also the Chairman & Executive President at Bluepharma Genéricos-Comércio de Medicamentos SA since 2014.
Additionally, he holds the position of Director at Treat U SA. In the past, he worked as a Director at Luzitin SA.
Postes actifs de Paulo Jorge Barradas de Oliveira Rebelo
| Sociétés | Poste | Début |
|---|---|---|
Bluepharma Indústria Farmacêutica SA
 Bluepharma Indústria Farmacêutica SA Pharmaceuticals: MajorHealth Technology Bluepharma Indústria Farmacêutica SA develops, manufactures, and markets pharmaceutical drugs The firm operates through the following business areas: Production of Pharmaceutical Drugs for Bluepharma and Other Companies; Research, Development, and Registration of Pharmaceutical Drugs; and Marketing of Generic Pharmaceutical Drugs. Its services include licensing, contract manufacturing, product development, and research and development. The company was founded in February 2001 and is headquartered in Coimbra, Portugal. | Directeur Général | - |
| Bluepharma Genéricos-Comércio de Medicamentos SA | Président | - |
Treat U SA
 Treat U SA BiotechnologyHealth Technology Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal. | Directeur/Membre du Conseil | - |
Anciens postes connus de Paulo Jorge Barradas de Oliveira Rebelo
| Sociétés | Poste | Fin |
|---|---|---|
Luzitin SA
 Luzitin SA Pharmaceuticals: MajorHealth Technology Luzitin SA provides photodynamic therapy and photodiagnosis solutions. The firm develops new compounds to improve the efficiency of photodynamic therapy in the treatment of cancer. The company was founded by Luís Arnaut in 2010 and is headquartered in Coimbra, Portugal. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Bluepharma Indústria Farmacêutica SA
Bluepharma Indústria Farmacêutica SA Pharmaceuticals: MajorHealth Technology Bluepharma Indústria Farmacêutica SA develops, manufactures, and markets pharmaceutical drugs The firm operates through the following business areas: Production of Pharmaceutical Drugs for Bluepharma and Other Companies; Research, Development, and Registration of Pharmaceutical Drugs; and Marketing of Generic Pharmaceutical Drugs. Its services include licensing, contract manufacturing, product development, and research and development. The company was founded in February 2001 and is headquartered in Coimbra, Portugal. | Health Technology |
Luzitin SA
Luzitin SA Pharmaceuticals: MajorHealth Technology Luzitin SA provides photodynamic therapy and photodiagnosis solutions. The firm develops new compounds to improve the efficiency of photodynamic therapy in the treatment of cancer. The company was founded by Luís Arnaut in 2010 and is headquartered in Coimbra, Portugal. | Health Technology |
| Bluepharma Genéricos-Comércio de Medicamentos SA | |
Treat U SA
Treat U SA BiotechnologyHealth Technology Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal. | Health Technology |